C07K 7/00
Peptides having 5 to 20 amino acids in a fully defined sequence
Official title: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
C07K7/00 (Peptides having 5 to 20 amino acids in a fully defined sequence) appears on 10,186 US grants and 13,301 published applications in this corpus.
Search patents in C07K- Granted patents
- 10,186
- Published applications
- 13,301
- Assignees
- 4,512
- Inventors
- 22,768
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 23 | 0 |
| 1977 | 26 | 0 |
| 1978 | 35 | 0 |
| 1979 | 8 | 0 |
| 1980 | 34 | 0 |
| 1981 | 39 | 0 |
| 1982 | 25 | 0 |
| 1983 | 38 | 0 |
| 1984 | 47 | 0 |
| 1985 | 37 | 0 |
| 1986 | 35 | 0 |
| 1987 | 52 | 0 |
| 1988 | 41 | 0 |
| 1989 | 40 | 0 |
| 1990 | 28 | 0 |
| 1991 | 47 | 0 |
| 1992 | 71 | 0 |
| 1993 | 63 | 0 |
| 1994 | 60 | 0 |
| 1995 | 103 | 0 |
| 1996 | 112 | 0 |
| 1997 | 180 | 0 |
| 1998 | 240 | 0 |
| 1999 | 188 | 0 |
| 2000 | 151 | 0 |
| 2001 | 182 | 22 |
| 2002 | 158 | 200 |
| 2003 | 178 | 366 |
| 2004 | 171 | 295 |
| 2005 | 132 | 360 |
| 2006 | 205 | 367 |
| 2007 | 192 | 292 |
| 2008 | 195 | 324 |
| 2009 | 216 | 389 |
| 2010 | 229 | 484 |
| 2011 | 227 | 447 |
| 2012 | 222 | 434 |
| 2013 | 372 | 632 |
| 2014 | 449 | 707 |
| 2015 | 486 | 704 |
| 2016 | 529 | 724 |
| 2017 | 500 | 689 |
| 2018 | 500 | 659 |
| 2019 | 561 | 717 |
| 2020 | 549 | 783 |
| 2021 | 484 | 733 |
| 2022 | 454 | 693 |
| 2023 | 355 | 640 |
| 2024 | 382 | 648 |
| 2025 | 328 | 564 |
| 2026 | 207 | 428 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Peptide libraries with non-canonical amino acids6 Oct 2026US 12,753,205 B2Regeneron Pharmaceuticals, Inc.
- VIPR2 antagonist peptide6 Oct 2026US 12,753,206 B2Ichimaru Pharcos Co., Ltd.
- Pharmaceutical composition for treatment or prevention of ischemic cardiovascular disease29 Sep 2026US 12,746,220 B2Industry-Academic Cooperation Foundation, Yonsei University
- Self-assembling peptides and hydrogels29 Sep 2026US 12,747,264 B2University of Virginia Patent Foundation
- Therapeutic peptides8 Oct 2026US 2026/0308201 A1Shape Therapeutics Inc.
- Using vefg165 fragments as a novel biomarker of inflammation to diagnose and guide medical care and treatments8 Oct 2026US 2026/0308202 A1Children's Medical Center Corporation
- P53 activator peptidomimetic macrocycles8 Oct 2026US 2026/0308203 A1Agency for Science, Technology and Research
- Cyclic compounds for treating cancer8 Oct 2026US 2026/0308204 A1University of South Florida
- New ternatin-type cyclopeptides for use in therapy8 Oct 2026US 2026/0308205 A1
Most cited
By later US patents
- Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof1,998US 5,143,854 AAffymax Technologies N.V. · 1992
- Array of oligonucleotides on a solid substrate1,585US 5,445,934 AAffymax Technologies N.V. · 1995
- Arrays of materials attached to a substrate1,410US 5,744,305 AAffymetrix, Inc. · 1998
- Very large scale immobilized polymer synthesis967US 5,424,186 AAffymax Technologies N.V. · 1995
- Method of detecting nucleic acids962US 5,800,992 A1998